L-Tyrosine
Tyrosine · 4-hydroxyphenylalanine · Tyr · Y · N-acetyl-L-tyrosine (NALT)
Last updated
At a glance
Overview
L-Tyrosine has quietly become the default catecholamine-precursor add-on in physique-focused supplement stacks — cheap, well-tolerated, and supported by a surprisingly robust military and sleep-deprivation literature. The mechanism is unglamorous but reliable: tyrosine is the rate-limiting substrate for dopamine and noradrenaline synthesis, and when the catecholamine system is being pushed hard (deep cuts, fasted training, sustained stim stacks, sleep loss, long cognitive blocks), substrate availability stops being trivial and starts being the difference between a sharp session and a flat one.
The community runs it three ways, all situational rather than chronic: as the focus leg of the caffeine + L-theanine + L-tyrosine pre-workout matrix, as stim-stack support during ephedrine / clenbuterol / yohimbine-heavy cut phases to delay the catecholamine-depletion crash, and as a cognitive bridge through sleep deprivation, shift work, or travel. None of these turn tyrosine into a stimulant on its own — standalone low-dose tyrosine in a rested, well-fed subject is subjectively close to placebo — but layered onto an already-stressed catecholamine system, the substrate effect is real and well-replicated.
"Tyrosine treatment was associated with significantly reduced adverse effects of stress and cold on mood and performance." — Banderet & Lieberman, Brain Research Bulletin (1989)
One useful calibration up front: the published cold-stress and sleep-deprivation protocols dose 100–150 mg/kg as a single oral bolus — roughly 8–12 g for an 80 kg subject — while the typical pre-workout serving is 500–2000 mg. Both work, but they work for different reasons, and conflating them is the most common dosing mistake on the forums. The sections below cover the full L-tyrosine dosage ladder from pre-workout doses up to the clinical 150 mg/kg protocols, the caffeine + theanine stack and stim-cycle pairings, documented side effects and the hard MAOI / levodopa contraindications, plus the practical fixes (empty stomach, free-form over NALT, situational not daily) that separate a noticeable effect from a placebo dose.
How L-Tyrosine works
L-Tyrosine is a conditionally essential aromatic amino acid that sits one enzymatic step upstream of the entire catecholamine cascade. Its nootropic effect is not pharmacological in the classical sense — it does not bind a receptor, gate an ion channel, or inhibit reuptake. Instead, it acts as substrate insurance for a neurotransmitter system that becomes substrate-limited under acute stress. Understanding this distinction is the whole game with tyrosine: the compound does effectively nothing in a rested, fed, low-demand state, and it produces its documented effects only when the catecholamine pool is being actively drawn down.
Tyrosine Hydroxylase and the Rate-Limiting Step#
The committed step of catecholamine synthesis is the hydroxylation of L-tyrosine to L-DOPA by tyrosine hydroxylase (TH). L-DOPA is then decarboxylated to dopamine, and dopamine is subsequently β-hydroxylated to noradrenaline and N-methylated to adrenaline in the relevant cell populations.
TH is the rate-limiting enzyme of the entire pathway and is normally regulated by end-product feedback inhibition — meaning that at rest, substrate availability is not limiting. Pushing more tyrosine into a relaxed system produces no measurable catecholamine output. The picture changes under high neuronal firing rates (cold exposure, sleep loss, prolonged multitasking, hypoxia, sympathetic-driven training in a deficit): feedback inhibition is lifted, TH operates closer to Vmax, and tyrosine availability becomes the bottleneck. This is the mechanistic basis for every positive trial in the literature.
"Tyrosine treatment was associated with significantly reduced adverse effects of stress and cold on mood and performance." — Banderet LE, Lieberman HR, Brain Research Bulletin (1989)
Practical takeaway: tyrosine is a stress-rescue compound, not a daily-everyday stimulant. The pre-workout, fasted-cardio, late-cut, and sleep-deprived use cases all map cleanly onto the "catecholamine pool is being depleted" scenario.
LNAA Transport and the Food Interaction#
Tyrosine crosses the blood–brain barrier on the large neutral amino acid transporter (LAT1), competing for the same carrier with phenylalanine, tryptophan, leucine, isoleucine, valine, and methionine. CNS uptake is therefore governed not by absolute plasma tyrosine but by the Tyr-to-LNAA ratio.
This is why a protein-rich meal flattens the effect — a whey shake floods the LAT1 pool with leucine and the other BCAAs, and the tyrosine bolus loses its competitive edge at the barrier. Dosing fasted, or with a carb-only vehicle that triggers insulin-mediated clearance of competing LNAAs into muscle, is the documented pattern for maximizing CNS delivery. This is also why N-acetyl-L-tyrosine (NALT) underperforms free L-tyrosine despite its better water solubility — the acetyl group is not efficiently cleaved in humans, and most of an oral NALT dose is excreted intact rather than raising plasma Tyr.
Working-Memory Preservation Under Acute Stress#
The strongest evidence base for tyrosine is in working memory and executive function under acute stressors that deplete catecholamines. Cold exposure, prolonged wakefulness, heat + exercise, and rapid multitasking all model the same underlying phenomenon: sympathetic overdrive drives noradrenaline release in the locus coeruleus and prefrontal cortex faster than the system can resynthesize it, and prefrontal-dependent task performance degrades.
"A single 150 mg/kg dose of tyrosine decreased the decrement in working memory during a night of cold exposure relative to placebo." — Mahoney CR, Castellani J, Kramer FM, Young A, Lieberman HR, Physiology & Behavior (2007)
"Acute tyrosine ingestion improved cognitive performance during prolonged exercise in hot conditions, with no differences seen for physical performance." — Coull NA, Watkins SL, Aldous JWF, et al., Medicine and Science in Sports and Exercise (2015)
Notice the consistent pattern across these trials: cognitive endpoints improve, raw physical output does not. Tyrosine is not an ergogenic aid in the contractile / strength / endurance sense. It preserves the decision-making and focus layer on top of the physical work, which is why it earns its place in pre-workout stacks and fasted-cut protocols but does nothing measurable for one-rep max or VO₂max.
A 2024 trial extended this picture to non-thermal cognitive load:
"L-tyrosine supplementation led to significantly improved performance accuracy on the multitasking framework versus placebo." — Childs E, et al., Nutrients / Physiology & Behavior (2024)
BDNF and the Chronic-Dosing Question#
Most of the tyrosine literature is acute. The chronic-dosing question — does repeated administration produce any structural neural benefit — is thinner, and the strongest signal comes from rodent work.
"Chronic L-tyrosine increased brain-derived neurotrophic factor (BDNF) levels and improved cognitive performance in animal models." — de Borba Gonçalves L, et al., Molecular and Cellular Biochemistry (2013)
BDNF upregulation is the same final common pathway implicated in the cognitive effects of exercise, semax, selank, and SSRIs, and is mechanistically plausible — sustained catecholaminergic tone drives BDNF transcription via CREB. Whether this translates to humans at supplemental doses is unresolved, and the community-reported tolerance to the subjective focus effect after 2–4 weeks of daily administration argues against parking tyrosine on a daily-forever schedule. Situational use, or 5-on / 2-off cycling, preserves responsiveness.
Adjacent Pathways: Thyroid, Melanin, and Why They Don't Matter Acutely#
Tyrosine is also the substrate for thyroid hormone synthesis (iodinated on thyroglobulin to form T3 and T4) and for melanin via tyrosinase. Neither pathway is meaningfully pushed by acute oral dosing in a euthyroid, iodine-replete subject — TH-mediated catecholamine synthesis has far higher substrate affinity, and the thyroid and melanin pathways are regulated upstream by TSH and α-MSH respectively, not by tyrosine availability.
The practical implication: tyrosine is not a thyroid booster, not a tanning agent, and the theoretical concerns around hyperthyroidism and melanoma history sit in the "biochemically plausible, clinically unproven, but worth flagging" category rather than the "documented harm" category. The one mechanism-driven hard contraindication is MAOI co-administration — loading substrate into a system where monoamine breakdown is blocked is the same scenario as a tyramine reaction, and the hypertensive-crisis risk is real.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 500–1000 mg | As needed | Documented entry-level range |
| Mid | 1500–2000 mg | As needed | Most commonly studied range |
| High | 3000–7000 mg | As needed | Situational, 30–45 min pre-stimulus on an empty stomach. Avoid co-administration with protein meals (LNAA competition blunts CNS uptake). Dosing after 3pm can disrupt sleep onset in caffeine-sensitive subjects. The clinical sleep-deprivation / cold-stress protocols use 100–150 mg/kg single oral boluses. |
Cycle length & outcomes
L-Tyrosine doesn't cycle the way hormonal compounds do. It's a substrate, not a signal — the catecholamine system only draws on supplemental tyrosine when firing rates are elevated and the endogenous pool is being depleted. That means the relevant question isn't "how many weeks on, how many off" but "how often before responsiveness flattens." The community consensus, backed by the acute-stress literature, is that situational dosing preserves the subjective effect indefinitely, while continuous daily administration produces noticeable tolerance within 2–4 weeks.
Cycle Length by Goal#
| Use Case | Cycle Pattern | Per-Dose Range | Timing |
|---|---|---|---|
| Pre-workout focus | Training days only, indefinite | 1.5–2 g | 30–45 min pre-session, fasted |
| Cut / fasted-training rescue | 4–8 week cut, daily AM | 2–3 g | First thing on waking, fasted |
| Stimulant-stack support (EC, clen, yohimbine) | Duration of the stim cycle, 2–6 weeks | 1–2 g × 2–3/day | Paired with each stim dose |
| Sleep-deprivation / shift bridge | Acute, situational | 100–150 mg/kg (8–12 g for 80 kg) | At onset of the sleep-deprived block, redose at half ~4–6 h later |
| General nootropic / focus | 5-on / 2-off, 4–6 week blocks | 1–2 g AM | On waking, fasted |
Onset and Duration#
Plasma tyrosine roughly doubles within 60–90 minutes of a free L-tyrosine bolus, and CNS uptake lags by another 30–60 minutes — which is why the published acute protocols administer the dose 30–60 minutes before the stressor, not at the moment of it. The functional window runs ~4–6 hours; redose timing for extended cognitive loads is built around that.
Subjectively, the first administration is often the most noticeable, especially when paired with caffeine on an empty stomach. Continuous daily dosing tends to dull the subjective lift by week 3–4, which is the main argument for situational or 5-on/2-off patterns rather than perpetual everyday use.
Loading and Tapering#
No loading phase is required or supported by the literature. The acute-stress studies achieve their effect on a single oral bolus (Mahoney et al. 2007; Coull et al. 2015) — there is no accumulation curve to build toward.
"A single 150 mg/kg dose of tyrosine decreased the decrement in working memory during a night of cold exposure relative to placebo." — Mahoney et al., Physiology & Behavior (2007)
No taper is required on cessation. Tyrosine doesn't suppress endogenous synthesis of anything — the body's baseline catecholamine production runs off dietary protein and is unaffected by stopping supplementation. Discontinuation is abrupt with no rebound, no withdrawal, and no HPGA implications.
Chronic vs. Acute Patterns#
The animal BDNF work suggests a separate, slower mechanism on top of the acute catecholamine-substrate effect:
"Chronic L-tyrosine increased brain-derived neurotrophic factor (BDNF) levels and improved cognitive performance in animal models." — de Borba Gonçalves et al., Mol Cell Biochem (2013)
This is preclinical and the translation to human cognition is speculative, but it provides a rationale for 4–6 week chronic blocks at moderate dose (1–2 g/day) when the goal is general cognitive support rather than situational focus. Subjective tolerance still applies — most experienced users build in a 1–2 week washout between blocks.
Bloodwork and Monitoring#
None routinely required. L-tyrosine has no documented impact on lipids, liver enzymes, kidney function, fasting glucose, or hormonal panels at supplemental doses. Subjects with diagnosed hyperthyroidism or active melanoma history are the exceptions — these warrant baseline thyroid panel and dermatologic clearance respectively, given the substrate role in T3/T4 and melanin synthesis.
The practical "monitoring" loop is subjective: track session quality and motivational baseline. When the pre-workout lift starts feeling like placebo, the protocol calls for a 1–2 week pause rather than a dose escalation.
Bottom line: situational, fasted, 30–45 min pre-stimulus, indefinite duration with built-in off days. There is no anabolic clock to manage and no recovery phase to engineer — the only variable worth tracking is whether the subjective effect is still landing.
Risks & mistakes
Common (most users)#
- Mild GI discomfort (nausea, heartburn, loose stools) — almost always a dissolution/vehicle issue with the powder. Mitigation: split doses above 3g, dissolve in warm water with a pinch of citric or ascorbic acid, or pair with a small carb hit (rice cake, dextrose) which also improves the Tyr/LNAA ratio.
- Mild headache — occasional report at the higher end of the clinical 100–150 mg/kg range. Usually resolves with hydration and a lower next-dose; if it tracks with caffeine co-administration, drop the caffeine first.
- Jitteriness or "wired" feeling — almost never from tyrosine alone; appears when stacked with high-dose caffeine, ephedrine, or yohimbine. Mitigation: pull caffeine back by 50–100mg, or add 100–200mg L-theanine to the pre-workout matrix.
- Sleep disruption when dosed late — administration after ~3pm can delay sleep onset in caffeine-sensitive subjects. Mitigation: keep all dosing pre-noon, or pre-stimulus only.
- Subjective tolerance / loss of "lift" — daily-everyday administration blunts the noticeable focus effect within 2–4 weeks. Mitigation: cycle 5-on / 2-off, or move to strictly situational pre-workout / pre-task use.
Uncommon (dose-dependent or individual)#
- Palpitations or elevated resting HR — almost exclusively a stacking issue (tyrosine + caffeine + ephedrine/clen/yohimbine in a cutting matrix). Back off the sympathomimetic, not the tyrosine. Anyone running a heavy stim-stack in contest prep should already be monitoring resting HR and blood pressure morning-fasted.
- Anxiety / overstimulation — individual variability is large. Reported across community accounts as both anxiolytic (working-memory rescue under load) and anxiogenic (in already-anxious subjects on a stimulant stack). If 2g pre-workout produces a wired-and-anxious profile rather than a focused one, drop to 500–1000mg or move administration to non-training cognitive-load days.
- Reduced levodopa efficacy — relevant only in subjects on Parkinson's therapy; tyrosine competes with L-DOPA at the LAT1 transporter at the blood–brain barrier and can blunt its CNS uptake.
- GI distress at "loading" doses (8–12g) — the clinical 100–150 mg/kg bolus is well above the typical pre-workout serving and is the dose range where nausea becomes more common. Split the dose 30 min apart if the full bolus doesn't sit well.
Rare but serious#
- Hypertensive episode when combined with MAO inhibitors — mechanistically the same scenario as the classic tyramine / aged-cheese reaction. Warning signs: sudden severe headache, flushing, sharply elevated blood pressure, chest pain. This is the one interaction that turns a benign amino acid into an ER visit.
- Theoretical thyroid hormone push in hyperthyroid / Graves' subjects — no strong evidence of clinically meaningful T3/T4 elevation at supplemental doses in euthyroid subjects, but worth flagging. Warning signs in susceptible subjects: tremor, heat intolerance, unexplained tachycardia, weight loss.
- Theoretical concern in active melanoma / progressing pigmented lesions — tyrosine is the melanin precursor via tyrosinase. Clinical relevance of oral dosing is unclear and likely small, but the risk/benefit doesn't favor administration in subjects with a melanoma history.
Hard contraindications#
- MAOIs (phenelzine, tranylcypromine, selegiline at MAO-A doses, moclobemide). Do not combine. Hypertensive crisis risk.
- Active levodopa therapy. Tyrosine blunts L-DOPA's CNS uptake via LAT1 competition. Separate timing under physician guidance or avoid.
- Documented melanoma or actively progressing dysplastic pigmented lesions. Theoretical but non-trivial concern via the melanin pathway.
- Uncontrolled hyperthyroidism / Graves' disease. Avoid loading-dose protocols until thyroid status is controlled.
"Tyrosine treatment was associated with significantly reduced adverse effects of stress and cold on mood and performance." — Banderet & Lieberman, Brain Res Bull 1989
Gender and PCT considerations#
None. L-tyrosine is a non-hormonal amino acid with no documented impact on the HPGA, no virilization risk, no aromatization, no androgenic activity, and no PCT requirement. Weight-based protocols (100–150 mg/kg in the cold-stress and sleep-deprivation literature) scale across the subject pool without sex-specific adjustment. It is one of the few compounds in this catalog where the female-subject dossier is identical to the male-subject dossier — same dose ladder, same stack partners, same caveats.
Stack & combine
FAQ — L-Tyrosine
Research & citations
5 studies cited on this page.
Conclusion
L-tyrosine is a staple nootropic for acute focus, stress resilience, and cognitive endurance, especially when the catecholamine system is under load. It shines in pre-workout and cognitive-demand stacks, delivering sharper mood and multitasking under stress without the harsh edge of pure stimulants.
Key takeaways:
- Typical pre-task dose: 500–2000 mg, oral, 30–45 min before stimulus, fasted or with black coffee/carbs (avoid protein meals for best CNS uptake)
- Acute high-stress protocols (sleep deprivation, cold, contest-peak): 100–150 mg/kg as a single oral dose, though community patterns typically use 5–20× lower for routine stacks (Banderet & Lieberman 1989)
- Stacking with caffeine (150–300 mg) and L-theanine (100–200 mg) is the community gold-standard for clean, long-duration focus
- Situational use (pre-workout, pre-task) maintains efficacy and reduces tolerance versus daily/continuous protocols
- Safety profile is exceptionally clean; main cautions are MAOI, levodopa, and melanoma history (see contraindications above)
- Documented to buffer focus and working memory in stress-load scenarios (Mahoney et al. 2007; Childs et al. 2024)
In any research protocol demanding reliable cognitive performance under pressure, L-tyrosine remains one of the most no-nonsense and cost-effective substrate support compounds available.